Compare FORTY & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORTY | GLPG |
|---|---|---|
| Founded | 1985 | 1999 |
| Country | Israel | Belgium |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 1997 | 2005 |
| Metric | FORTY | GLPG |
|---|---|---|
| Price | $163.27 | $34.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $31.33 |
| AVG Volume (30 Days) | 541.0 | ★ 122.6K |
| Earning Date | 11-20-2025 | 02-11-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $3,016,039,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | N/A | $0.49 |
| P/E Ratio | $36.65 | ★ N/A |
| Revenue Growth | ★ 11.45 | 10.31 |
| 52 Week Low | $82.52 | $22.36 |
| 52 Week High | $190.56 | $37.78 |
| Indicator | FORTY | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 67.02 |
| Support Level | $165.93 | $32.13 |
| Resistance Level | $170.01 | $34.48 |
| Average True Range (ATR) | 2.19 | 0.81 |
| MACD | -1.18 | 0.08 |
| Stochastic Oscillator | 33.13 | 85.81 |
Formula Systems (1985) Ltd is a holding company that, through its subsidiaries, provides information technology services. The company organizes itself into operating segments: The Matrix segment, which generates the majority of revenue, provides software development and existing software expansion services. The Sapiens segment provides software development services for the insurance industry. The Magic Software segment provides vendor management systems and workforce management services, which include accounting and finance, human resources, Michpal, ZAP Group, and Others. The majority of the company's revenue comes from Israel.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.